Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Carfilzomib by Amgen for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Carfilzomib by Amgen for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....
Carfilzomib by Amgen for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...